These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 3156110)

  • 21. In vivo interaction of anti-cancer drugs with misonidazole or metronidazole: cyclophosphamide and BCNU.
    Tannock IF
    Br J Cancer; 1980 Dec; 42(6):871-80. PubMed ID: 7459221
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combination of interleukin-2 and irradiation in therapy of murine tumors.
    Hunter N; Nakayama T; Ito H; Woo S; Milas L
    Clin Exp Metastasis; 1992 Nov; 10(6):431-6. PubMed ID: 1451353
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Anti-tumor activities of direct current (DC) therapy combined with fractionated radiation or chemotherapy].
    Nakayama T; Ito H; Hashimoto S
    Nihon Igaku Hoshasen Gakkai Zasshi; 1988 Oct; 48(10):1269-75. PubMed ID: 3265497
    [No Abstract]   [Full Text] [Related]  

  • 24. Tumor-specific chemoimmunotherapy of murine fibrosarcoma using tumor-specific transplantation antigen, cyclophosphamide, and interleukin-2.
    Naito K; Nomi S; Komichi H; Ueda Y; Yamagishi H; Oka T; Pellis NR; Kahan BD
    Cancer Detect Prev; 1992; 16(5-6):321-7. PubMed ID: 1361881
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Studies on lymphokine-activated killer (LAK) cell: accumulation in tumor tissue and the therapeutic effects of adoptive immunotherapy].
    Wakizaka Y
    Hokkaido Igaku Zasshi; 1992 Jul; 67(4):475-87. PubMed ID: 1330859
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antitumor activity of nigericin and 5-(N-ethyl-N-isopropyl)amiloride: an approach to therapy based on cellular acidification and the inhibition of regulation of intracellular pH.
    Hasuda K; Lee C; Tannock IF
    Oncol Res; 1994; 6(6):259-68. PubMed ID: 7865901
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of forphenicinol, a small molecular immunomodifier, in combination with cyclophosphamide on growth of and immunity to syngeneic murine tumors.
    Nitta K; Tanaka T; Takeuchi M
    Cancer Treat Rep; 1985 Mar; 69(3):285-91. PubMed ID: 3978657
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Diminution of cyclophosphamide-induced suppression of antitumor immunity by an immunomodulator PS-K and combined therapeutic effects of PS-K and cyclophosphamide on transplanted tumor in rats.
    Mizushima Y; Yuhki N; Hosokawa M; Kobayashi H
    Cancer Res; 1982 Dec; 42(12):5176-80. PubMed ID: 7139621
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Response of radiation-induced fibrosarcoma-1 in mice to cyclophosphamide monitored by in vivo 31P nuclear magnetic resonance spectroscopy.
    Li SJ; Wehrle JP; Rajan SS; Steen RG; Glickson JD; Hilton J
    Cancer Res; 1988 Sep; 48(17):4736-42. PubMed ID: 3409214
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Radiation response of "clonogenic" tumor cell release from NFSA2ALM1 tumors.
    Suzuki N
    Radiat Res; 1984 Jun; 98(3):649-55. PubMed ID: 6729057
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tumor sensitization and protection: influence of stromal injury on estimates of dose modification.
    Williams MV; Rojas A; Denekamp J
    Int J Radiat Oncol Biol Phys; 1984 Sep; 10(9):1545-9. PubMed ID: 6090359
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Interaction of SR-4233 with hyperthermia and radiation in the FSaIIC murine fibrosarcoma tumor system in vitro and in vivo.
    Herman TS; Teicher BA; Coleman CN
    Cancer Res; 1990 Aug; 50(16):5055-9. PubMed ID: 2379171
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Response of the FSaII fibrosarcoma to antiangiogenic modulators plus cytotoxic agents.
    Teicher BA; Holden SA; Ara G; Northey D
    Anticancer Res; 1993; 13(6A):2101-6. PubMed ID: 7507654
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of sequencing of the total course of combined hyperthermia and radiation on the RIF-1 murine tumor.
    Mittal B; Emami B; Sapareto SA; Taylor FH; Abrath FG
    Cancer; 1984 Dec; 54(12):2889-97. PubMed ID: 6498765
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Increases in tumor response by pentoxifylline alone or in combination with nicotinamide.
    Lee I; Kim JH; Levitt SH; Song CW
    Int J Radiat Oncol Biol Phys; 1992; 22(3):425-9. PubMed ID: 1531211
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of continuous administration of interleukin 2 on active specific chemoimmunotherapy with extracted tumor-specific transplantation antigen and cyclophosphamide.
    Naito K; Pellis NR; Kahan BD
    Cancer Res; 1988 Jan; 48(1):101-8. PubMed ID: 3257158
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Induction thermochemotherapy increases therapeutic gain factor for the fractionated radiotherapy given to a mouse fibrosarcoma.
    Kuroda M; Urano M; Nishimura Y; Reynolds R
    Int J Radiat Oncol Biol Phys; 1997 May; 38(2):411-7. PubMed ID: 9226330
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tumor bed effect-induced reduction of tumor radiocurability through the increase in hypoxic cell fraction.
    Milas L; Hunter N; Peters LJ
    Int J Radiat Oncol Biol Phys; 1989 Jan; 16(1):139-42. PubMed ID: 2912935
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of oxygen level on the enhancement of tumor response to radiation by perfluorochemical emulsions or a bovine hemoglobin preparation.
    Teicher BA; Herman TS; Hopkins RE; Menon K
    Int J Radiat Oncol Biol Phys; 1991 Sep; 21(4):969-74. PubMed ID: 1917627
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Survival of leukemic cells in a dormant state following cyclophosphamide-induced cure of strongly immunogenic mouse leukemia (DL811).
    Matsuzawa A; Takeda Y; Narita M; Ozawa H
    Int J Cancer; 1991 Sep; 49(2):303-9. PubMed ID: 1879974
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.